A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

NCT06019559 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: K-757 120 mg BID and K-833 100 mg BID
DRUG: K-757 120 mg BID and matching placebo to K-833
DRUG: Matching placebo to K-757 and matching placebo to K-833

Sponsor

Kallyope Inc.